reports
Rail Vision CEO: Concluding 2025 with a Strong Cash Position, Zero Deb...
Rail Vision CEO: Concluding 2025 with a Strong Cash Position, Zero Debt, Commercialization Gains, Global Expansion and Powerful Partnerships. Quantum Rail Innovation Ahead Ra’anana, Israel, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Rail Vision Ltd. (Nasdaq: RVSN) (“Rail Vision” or the “Company”), an early commercialization stage technology company seeking to revolutionize railway safety and the data-related market, today issued a corporate update to its shareholders from the Company’s Chief Executive Officer, Mr. David BenDavid. Dear Shareholders, 2025 was a transformative year for Rail Vision....
MariMed Announces Fourth Quarter and Full Year 2025 Earnings Date
MariMed Announces Fourth Quarter and Full Year 2025 Earnings Date NORWOOD, Mass., Feb. 11, 2026 (GLOBE NEWSWIRE) -- . (“MariMed” or the “Company”) (CSE: MRMD) (OTCQX: MRMD), a leading cannabis consumer packaged goods company and retailer, announced today it will report its fourth quarter and full year 2025 financial results on March 11, 2026 after the markets close. Management will host a conference call on March 12, 2026 at 8:00 a.m. EDT to discuss financial results. A webcast will be available and can be accessed via MariMed’s Investor Relations website at . A playback of the call will...
NorthStrive Biosciences Signs Definitive License Agreement for Commerc...
NorthStrive Biosciences Signs Definitive License Agreement for Commercialization of EL-22 and EL-32, a Myostatin-Engineered Probiotic for Muscle Preservation in Animal Health NEWPORT BEACH, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- NorthStrive Biosciences Inc. (“NorthStrive”), a wholly owned subsidiary of PMGC Holdings Inc. (NASDAQ: ELAB) (the “Company,” “PMGC,” “we,” or “our”), today announced that it has executed a definitive, exclusive license agreement (“License Agreement”) with Modulant Biosciences LLC (“Modulant”), following the previously announced binding term sheet dated May 12, ...
BioRestorative Announces Positive Outcome from Type B Meeting with FDA
BioRestorative Announces Positive Outcome from Type B Meeting with FDA BioRestorative completed a Type B meeting with the U.S. Food and Drug Administration (“FDA”) regarding a potential accelerated Biologics License Application (“BLA”) approval pathway for the Fast-Track-Designated BRTX-100 program for the treatment of chronic lumbar disc disease (“cLDD”)Consistent positive clinical safety endpoints from BioRestorative’s ongoing 99 patient Phase 2 clinical trial of BRTX-100 in cLDD were discussed in the meeting and the FDA did not raise any clinical safety concerns FDA endorsed the proposed...
Great Lakes Dredge & Dock to Join the Saltchuk Family of Companies
Great Lakes Dredge & Dock to Join the Saltchuk Family of Companies Great Lakes Shareholders to receive $17.00 per Share in All-Cash Transaction Valued at $1.5 Billion HOUSTON and SEATTLE, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Great Lakes Dredge & Dock Corporation ("Great Lakes" or the “Company”) (NASDAQ: GLDD), the largest provider of dredging services in the United States, and Saltchuk Resources, Inc. ("Saltchuk"), a privately owned family of diversified freight transportation, marine service, and energy distribution companies, today announced a definitive agreement for Saltchuk to acquire...
Nuvectis Pharma, Inc. Reports 2025 Financial Results and Business High...
Nuvectis Pharma, Inc. Reports 2025 Financial Results and Business Highlights FORT LEE, N.J., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today reported its financial results for the year ended December 31, 2025 and provided an update on recent business progress. Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, commented, “2025 was an eventfu...
PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-...
PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results The Company is in Advanced Stages of Commercial U.S. Partnership Discussions for D-PLEX₁₀₀ Positive FDA Pre-NDA Feedback Supports Rolling NDA Review; Submission Expected to Begin by the End of the First Quarter of 2026 Conference Call Scheduled for Today at 8:30 AM ET PETACH TIKVA, Israel, Feb. 11, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiv...
Geron Plans to Announce Fourth Quarter and Full Year 2025 Financial Re...
Geron Plans to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026 FOSTER CITY, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that it will release its fourth quarter and full year 2025 financial results and business highlights before the market opens on Wednesday, February 25, 2026 via press release, which will be available on the section of the Company’s website. Geron will host a conference call and webca...
Berjaya Land Berhad: 1 director
A director at Berjaya Land Berhad sold 8,000,000 shares at 0.310MYR and the significance rating of the trade was 61/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years c...
Exodus Movement, Inc. January 2026 Treasury Update and Monthly Metrics
Exodus Movement, Inc. January 2026 Treasury Update and Monthly Metrics Company holds 1,694 BTC OMAHA, Neb., Feb. 11, 2026 (GLOBE NEWSWIRE) -- . (NYSE American: EXOD) ("Exodus" or “the company”), a leading self-custodial cryptocurrency platform, today announced an update to selected digital asset holdings of Exodus’ corporate treasury, as well as updated user and exchange provider processed volume metrics, as of January 31, 2026:Exodus CFO James Gernetzke remarked: “At Exodus, we have been navigating crypto markets for almost 11 years, so we have significant experience continuing to buil...
Inter&Co Reports Record Results, Driven by 36% Credit Expansion and 45...
Inter&Co Reports Record Results, Driven by 36% Credit Expansion and 45% Net Income Growth in 2025 MIAMI, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Inter&Co Inc. (NASDAQ: INTR) the leading digital bank providing financial and commerce services to over 43 million customers, reported its financial results today for the fourth quarter of 2025. 2025 Highlights:Inter delivered another year of exceptional growth across key metrics, sustaining consistent profitability while accelerating market expansion. Client Growth: Added a record-breaking 4.4 million new active clients in 2025, bringing total activ...
- Jo Yee Ng
KIP REIT (KIP MK) - More Than Meets The Yield
More Than Meets The Yield Highlights The defensive REIT offers investors an attractive yield of 7.6% in FY26F, with re-rating potential from its acquisition-led growth and improving liquidity. DPU has grown under the current CEO, and we forecast a 4% three-year CAGR in DPU during FY25-28F, underscoring management’s execution capability and focus on unitholder returns. Initiate coverage with BUY and a DDM-based target price of RM1.15.
Form 8.3 - Picton Property Income Limited
Form 8.3 - Picton Property Income Limited 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser:Rathbones Group Plc(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c) Name of offeror/offeree in relation to whose relevant securities thi...
Vertex Announces Fourth Quarter and Full Year 2025 Financial Results
Vertex Announces Fourth Quarter and Full Year 2025 Financial Results KING OF PRUSSIA, Pa., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ: VERX) (“Vertex” or the “Company”), a leading global provider of indirect tax solutions, today announced financial results for its fourth quarter and full year ended December 31, 2025. “In 2025, Vertex delivered double-digit revenue growth and meaningful profitability improvements while making important investments in the future,” said Christopher Young, President and Chief Executive Officer of Vertex. “We sustained our market position as the l...
SAIC Announces Preliminary Unaudited Fourth Quarter and Full Fiscal Ye...
SAIC Announces Preliminary Unaudited Fourth Quarter and Full Fiscal Year 2026 Financial Results and Updated Fiscal Year 2027 Guidance RESTON, Va., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Science Applications International Corp. (NASDAQ: ), a leading mission integrator supporting defense, space, intelligence and civilian agencies, today announced unaudited preliminary financial results for the fiscal fourth quarter and full fiscal year 2026 and updated its financial guidance for fiscal year 2027. The Company’s announcement of unaudited preliminary financial results and updated guidance was prima...
Form 8.3 - Bluefield Solar Income Fund Ltd
Form 8.3 - Bluefield Solar Income Fund Ltd 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser:Rathbones Group Plc(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c) Name of offeror/offeree in relation to whose relevant securities th...
Affle 3i Ltd: 1 director
A director at Affle 3i Ltd bought 48,000 shares at 1,657.709INR and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clea...
BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Nav...
BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting RESEARCH TRIANGLE PARK, N.C., Feb. 11, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: BCRX) today announced that the company will present nine abstracts from its hereditary angioedema (HAE) portfolio at the 2026 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting taking place in Philadelphia from February 27-March 2, 2026. Data include six abstracts featuring new clinical trial and real-world outcomes with ORLADEYO® (berotralsta...
Kelly Appoints Patrick McCall as Chief Growth Officer
Kelly Appoints Patrick McCall as Chief Growth Officer Industry leader will oversee company-wide growth acceleration efforts TROY, Mich., Feb. 11, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: KELYA, KELYB), a global specialty talent solutions provider, has appointed Patrick McCall as chief growth officer, effective Feb. 16, 2026. McCall is joining the company’s senior leadership team, reporting to Kelly CEO , and responsible for accelerating Kelly’s organic growth and delivering industry-leading capabilities to clients and candidates. “Pat is a growth-obsessed leader who will help bring to bear t...
NervGen Pharma to Present at Unite2Fight Paralysis’ 20th Annual Scienc...
NervGen Pharma to Present at Unite2Fight Paralysis’ 20th Annual Science and Advocacy Symposium Adam Rogers, MD, President and Chief Executive Officer of NervGen to present and discuss clinical data from the Phase 1b/2a CONNECT SCI Study demonstrating durable improvement in function, independence, and quality of life in chronic spinal cord injury VANCOUVER, British Columbia, Feb. 11, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for sp...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.